Benefit-risk assessment of incretin and other anti-diabetic agents in type 2 diabetes using a stochastic multicriteria acceptability analysis model

To the Editor:Incretin-based therapies for type 2 diabetes mellitus(T2DM)include incretin mimetics of glucagonlike peptide-1 receptor agonists(GLP-1 RAs)and incretin enhancers of dipeptidyl peptidase-4(DPP-4)inhibitors.[1]With good hypoglycemic effects of incretin-based drugs that show no weight gain or hypoglycemia risk,these drugs are increasingly used in patients with T2DM.